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Chronic Myeloid Leukaemia (CML), a cancer with a known driver 
CML is characterised by a reciprocal translocation [t(9;22)(q34;q11)] between 
chromosomes 9 and 22, producing the Philadelphia chromosome. This abnormal 
chromosome carries a fusion gene, BCR-ABL that is translated into the constitutively 
active BCR-ABL protein tyrosine kinase (TK). In haemopoietic stem cells this protein 
activates a cascade of signalling pathways resulting in increased survival, proliferation, (1) 
altered adhesion (2) and limited growth factor dependence. The progeny of these cells 
outgrow the normal cells to propagate the disease, CML. Functionally, protein kinases 
interact with ATP and the introduction of an ATP competitive inhibitor of BCR-ABL 
kinase was a major milestone in CML therapy. In 1998, the first TK inhibitor (TKI) 
imatinib was introduced to the clinic. Consequently, ABL kinase targeted (3) small 
molecule inhibitors captured the market with consecutive development of broad spectrum 
inhibitors like dasatinib and more potent inhibitors like nilotinib.  
CML therapeutics: Good, better, best. Never let it rest. 
TKI is the drug class of choice in chronic phase CML, but these drugs are less effective in 
accelerated phase or blast crisis. Even in chronic phase drug resistance due to kinase 
domain mutations, overexpression of BCR-ABL and other mechanisms has been 
problematic. Newer TKIs, such as dasatinib and nilotinib, were developed to circumvent 
this issue and recent TKIs, including danusertib and ponatinib, are in clinical trial for the 
most resistant mutation, T315I. In addition to drug resistance, quiescent CML stem cells 
are insensitive to all TKIs thus far tested and are thought responsible for disease 
persistence (4). The scientific community is concerned that persistent CML stem cells may 
be independent of BCR-ABL activity for survival and proliferation and thus cannot be 
eradicated by TKI treatment alone. This has led the pharmaceutical industry to try to 
synthesise new classes of drugs to combat CML, seeking cure.  
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Autophagy: ‘Live and let die’ 
As has been demonstrated in solid neoplasms, TKI treatment initiates the process of 
autophagy in primary CML cells (5). Autophagy is a recycling process of vital cellular 
constituents, damaged organelles and harmful materials that is initiated following 
enclosure in double membrane bound autophagy vacuoles (AV) and delivery to lysosomes 
for proteolytic degradation. Autophagy can be initiated in starvation due to withdrawal of 
growth factor signalling. In CML, BCR-ABL mimics growth factor stimulation (6) thus its 
inhibition by TKI may induce autophagy in a similar fashion. Physiological autophagy is 
essential for cellular homeostasis and the death signal can promote cellular demise through 
autophagy, either independent of, or linked to apoptosis (7). Though suppression of 
autophagy may be associated with cell transformation and carcinogenesis, malignant cells 
can also induce autophagy as a protective way to relieve therapy induced stress as 
evidenced in CML after TKI treatment (5). The decisions between ‘survival’ or ‘death’  
through induction of autophagy in malignancy likely depends on cellular context and 
signalling intensity (8). Tackling ‘survival’ autophagy in CML (5) may therefore provide 
new hope for eradication of the disease. CHOICES (CHlorOquine and Imatinib 
Combination to Eliminate Stem cells), a phase II randomised clinical trial (ISCRTN No. 
61568166) is currently completing a safety run-in period combining TKI with 
Hydroxychloroquine (HCQ) before being opened to further patients in the UK.  
Hydroxychloroquine:  A new spin on an old concept 
HCQ is a derivative of the antimalarial drug chloroquine with significantly reduced 
toxicity. These drugs have been prescribed for rheumatic diseases, several inflammatory 
conditions and immune related skin disorders (9). Most recently these drugs have been used 
in conjunction with anti-neoplastic chemo-or radiotherapies, where induction of autophagy 
has been shown to function as an escape mechanism for neoplastic cells to evade death. 
These quinolone derivatives are lysosomotropic agents with weak DNA intercalating 
properties. The cytotoxic and anti-inflammatory effects of these drugs are exerted mainly 
through their lysosomal function. Lysosomes or ‘suicide bags’ are the key component of 
final degradation of AV.  These weak bases (quinolones) penetrate the plasma membrane 
and get concentrated in the lysosome, where protonation of the drug increases the pH of 
the lysosomal environment. This in turn results in inhibition of fusion between lysosome 
and AV, preventing further proteolytic degradation, thus working as an autophagy 
inhibitor. Apart from accumulation of AV, this process instigates a series of events which 
may occur collectively or selectively in a tissue specific manner. The increased pH inhibits 
Toll Like Receptor (TLR) activities, receptor recycling, alteration of MHC assembly and 
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sequestration of membrane ceramides which limits membrane turnover (10). These are 
probably the critical mechanisms for the anti-inflammatory actions of the drug. The 
consequent expansion of lysosome and increased permeabilisation of lysosomal membrane 
can trigger release of enzymes like cathepsin B and insertion of Bax into mitochondrial 
membrane, followed by release of cytochrome C and loss of mitochondrial membrane 
potential (11). Eventual cell death can ensue by p53 dependent pathways, either by caspase 
mediated apoptosis (12) or in a caspase independent manner (13).   
The chemo-sensitising properties of these drugs can also be attributed to inhibition of drug 
transport by ATP binding cassette (ABC) transporters. ABC transporters, like MultiDrug 
Resistance protein (MDR) or Multidrug Resistance-associated Protein 1 (MRP1), have 
been implicated in imatinib resistance (14) and therefore this plausible influence of HCQ on 
TKI treatment requires further investigation. 
Complete cure of CML: hope and despair 
HCQ is not a ‘clean’ autophagy inhibitor as it possesses multiple mechanisms of action. In 
addition long term use of HCQ can rarely cause retinopathy, myopathy and neuropathic 
complications, leading to caution with its use in CML patients. The drug can be used at up 
to 1200 mg/day (15) and for CML patients in the CHOICES trial is being used at 800 
mg/day for 12 months, which should provide a steady state blood concentration of 
approximately 6µM (16), well within the autophagy inhibitory range in vitro. Other 
presently available inhibitors of autophagy, like, 3 methyladenine, wortmannin and 
bafilomycin A1, are quite non-specific and unsuitable for clinical use. Moreover, the 
potential to inhibit autophagy is likely to prove critical as the majority of alternative 
therapies for CML, including proteosome inhibitors (17), protein phosphatase 2A activator 
(18), farnesyl transferase inhibitors (19) and histone deacetylase inhibitors, are all capable of  
autophagy induction. Pharmaceutical companies are actively exploring development of 
specific autophagy inhibitors.   
Concluding remarks 
The mechanism of the survival/death effect of autophagy induced by chemotherapeutic 
agents in CML cells needs to be elucidated. Whilst HCQ with TKI in CML patients should 
provide proof of concept, it is hoped that in the future “cleaner” autophagy inhibitors may 
enhance eradication of CML and other forms of cancer with less off target toxicity.  
The authors declare no competing financial interests. 
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